XML 32 R13.htm IDEA: XBRL DOCUMENT
v3.24.1.1.u2

Long-Term Investments | 3 Months Ended | 12 Months Ended
--- | --- | ---
Mar. 31, 2024 | Dec. 31, 2023
Long-Term Investments [Abstract] |  |
LONG-TERM INVESTMENTS | 6. LONG-TERM INVESTMENTS
(1) | The ownership percentages of each investee are listed as follows:
|  | Ownership percentage |  |  |
|  | March 31, |  |  | December 31, |  |  | Accounting
Name of related party |  | 2024 |  |  | 2023 |  |  | treatments
Braingenesis Biotechnology Co., Ltd. |  |  | 0.17 | % |  |  | 0.17 | % |  | Cost Method
Genepharm Biotech Corporation |  |  | 0.67 | % |  |  | 0.67 | % |  | Cost Method
BioHopeKing Corporation |  |  | 5.90 | % |  |  | 5.90 | % |  | Cost Method
BioFirst Corporation |  |  | 18.68 | % |  |  | 18.68 | % |  | Equity Method
Rgene Corporation |  |  | 26.65 | % |  |  | 26.65 | % |  | Equity Method
(2) | The extent the investee relies on the company for its business are summarized as follows:
Name of related party |  | The extent the investee relies on the Company for its business
Braingenesis Biotechnology Co., Ltd. |  | No specific business relationship
Genepharm Biotech Corporation |  | No specific business relationship
BioHopeKing Corporation |  | Collaborating with the Company to develop and commercialize drugs
BioFirst Corporation |  | Loaned from investee and provides research and development support service
Rgene Corporation |  | Collaborating with the Company to develop and commercialize drugs
(3) | Long-term investment mainly consists of the following:
|  | March 31, 2024 |  |  | December 31, 2023 |
|  | (Unaudited) |  |  |  |
Non-marketable Cost Method Investments, net |  |  |  |  |  |
Braingenesis Biotechnology Co., Ltd. |  | $ | 6,904 |  |  | $ | 7,213 |
Genepharm Biotech Corporation |  |  | 21,078 |  |  |  | 22,021 |
BioHopeKing Corporation |  |  | 782,995 |  |  |  | 818,018 |
Sub total |  |  | 810,977 |  |  |  | 847,252 |
Equity Method Investments, net |  |  |  |  |  |  |  |
BioFirst Corporation |  |  | 1,663,537 |  |  |  | 1,680,488 |
Rgene Corporation |  |  | - |  |  |  | - |
Total |  | $ | 2,474,514 |  |  | $ | 2,527,740 |
(a) | BioFirst Corporation (the “BioFirst”):
The Company holds an equity interest in BioFirst Corporation, accounting for its equity interest using the equity method to accounts for its equity investment as prescribed in ASC 323, Investments—Equity Method and Joint Ventures (“ASC 323”). Equity method adjustments include the Company’s proportionate share of investee’s income or loss and other adjustments required by the equity method. As of March 31, 2024 and December 31, 2023, the Company owns 18.68% and 18.68% common stock shares of BioFirst, respectively. The Company made a prepayment for equity investment in BioFirst to purchase additional shares to be issued by BioFirst in the aggregate amount of $2,688,578, recorded as prepayment for long-term investments as of December 31, 2022. On July 19, 2023, the Company successfully completed the registration process for this investment. The initial prepayment was $1,895,556, which is a portion of the prepayment as of December 31, 2022, and was converted into 994,450 shares of BioFirst stock. As of March 31, 2024, the amount of prepayment for long-term investments in BioFirst is $1,124,842. Summarized financial information for the Company’s equity method investee, BioFirst, is as follows: Balance Sheets
|  | March 31, 2024 |  |  | December 31, 2023 |
|  | (Unaudited) |  |  |  |
Current Assets |  | $ | 1,439,444 |  |  | $ | 1,451,877 |
Non-current Assets |  |  | 651,560 |  |  |  | 686,206 |
Current Liabilities |  |  | 2,663,111 |  |  |  | 2,286,058 |
Non-current Liabilities |  |  | 101,908 |  |  |  | 347,193 |
Stockholders’ Equity (Deficit) |  |  | (674,015 | ) |  |  | (495,168 | )
Statement of Operations
|  | Three months Ended March 31, |
|  | 2024 |  |  | 2023 |
|  | (Unaudited) |
Net sales |  | $ | 363 |  |  | $ | - |
Gross profit |  |  | 220 |  |  |  | - |
Net loss |  |  | (203,077 | ) |  |  | (406,233 | )
Share of losses from investments accounted for using the equity method |  |  | - |  |  |  | - |
(b) | Rgene Corporation (the “Rgene”)
Both Rgene and the Company are under common control by Dr. Tsung-Shann Jiang, the CEO and Chairman of the BioLite Inc. Since Dr. Tsung-Shann Jiang is able to exercise significant influence, but not control, over the Rgene, the Company determined to use the equity method to account for its equity investment as prescribed in ASC 323, Investments—Equity Method and Joint Ventures (“ASC 323”). Equity method adjustments include the Company’s proportionate share of investee’s income or loss and other adjustments required by the equity method. As of March 31, 2024 and December 31, 2023, the Company owns 26.65% and 26.65% Common Stock shares of Rgene, respectively. Summarized financial information for the Company’s equity method investee, Rgene, is as follows: Balance Sheets
|  | March 31, 2024 |  |  | December 31, 2023 |
|  | (Unaudited) |  |  |  |
Current Assets |  | $ | 49,496 |  |  | $ | 50,538 |
Non-current Assets |  |  | 238,193 |  |  |  | 250,716 |
Current Liabilities |  |  | 2,535,581 |  |  |  | 2,591,960 |
Non-current Liabilities |  |  | 1,194 |  |  |  | 811 |
Shareholders’ Deficit |  |  | (2,249,086 | ) |  |  | (2,291,517 | )
Statement of Operations
|  | Three months Ended March 31, |
|  | 2024 |  |  | 2023 |
|  | (Unaudited) |
Net sales |  | $ | - |  |  | $ | - |
Gross Profit |  |  | - |  |  |  | - |
Net loss |  |  | (56,567 | ) |  |  | (81,842 | )
Share of loss from investments accounted for using the equity method |  |  | - |  |  |  | - |
(4) | Disposition of long-term investment
During the three months ended March 31, 2024 and 2023, there is no disposition of long-term investment.
(5) | Losses on Equity Investments
The components of losses on equity investments for each period were as follows:
|  | Three months Ended March 31, |
|  | 2024 |  |  | 2023 |
|  | (Unaudited) |
Share of equity method investee losses |  | $ | - |  |  | $ | - |
| 6. LONG-TERM INVESTMENTS
(1) | The ownership percentages of each investee are listed as follows:
|  | Ownership percentage |  |  |
|  | December 31, |  |  | December 31, |  |  | Accounting
Name of related party |  | 2023 |  |  | 2022 |  |  | treatments
Braingenesis Biotechnology Co., Ltd. |  |  | 0.17 | % |  |  | 0.17 | % |  | Cost Method
Genepharm Biotech Corporation |  |  | 0.67 | % |  |  | 0.67 | % |  | Cost Method
BioHopeKing Corporation |  |  | 5.90 | % |  |  | 5.90 | % |  | Cost Method
BioFirst Corporation |  |  | 18.68 | % |  |  | 15.51 | % |  | Equity Method
Rgene Corporation |  |  | 26.65 | % |  |  | 26.65 | % |  | Equity Method
(2) | The extent the investee relies on the company for its business are summarized as follows:
Name of related party |  | The extent the investee relies on the Company for its business
Braingenesis Biotechnology Co., Ltd. |  | No specific business relationship
Genepharm Biotech Corporation |  | No specific business relationship
BioHopeKing Corporation |  | Collaborating with the Company to develop and commercialize drugs
BioFirst Corporation |  | Loaned from the investee and provides research and development support service
Rgene Corporation |  | Collaborating with the Company to develop and commercialize drugs
(3) | Long-term investment mainly consists of the following:
|  | December 31, 2023 |  |  | December 31, 2022 |
Non-marketable Cost Method Investments, net |  |  |  |  |  |
Braingenesis Biotechnology Co., Ltd. |  | $ | 7,213 |  |  | $ | 7,169 |
Genepharm Biotech Corporation |  |  | 22,021 |  |  |  | 21,887 |
BioHopeKing Corporation |  |  | 818,018 |  |  |  | 813,014 |
Subtotal |  |  | 847,252 |  |  |  | 842,070 |
Equity Method Investments, net |  |  |  |  |  |  |  |
BioFirst Corporation(a) |  |  | 1,680,488 |  |  |  | - |
Rgene Corporation(b) |  |  | - |  |  |  | - |
Total |  | $ | 2,527,740 |  |  | $ | 842,070 |
(a) | BioFirst Corporation (the “BioFirst”):
The Company holds an equity interest in BioFirst Corporation, accounting for its equity interest using the equity method to accounts for its equity investment as prescribed in ASC 323, Investments—Equity Method and Joint Ventures (“ASC 323”). Equity method adjustments include the Company’s proportionate share of investee’s income or loss and other adjustments required by the equity method. As of December 31, 2023 and 2022, the Company owns 18.68% and 15.51% common stock shares of BioFirst, respectively. The Company made a prepayment for equity investment in BioFirst to purchase additional shares to be issued by BioFirst in the aggregate amount of $2,688,578, recorded as prepayment for long-term investments as of December 31, 2022. On July 19, 2023, the Company successfully completed the registration process for this investment. The initial prepayment was $1,895,556, which is a portion of the prepayment as of December 31, 2022, and was converted into 994,450 shares of BioFirst stock. As of December 31, 2023, the amount of prepayment for long-term investments in Biofirst is $1,124,842. Summarized financial information for the Company’s equity method investee, BioFirst, is as follows: Balance Sheet
|  | December 31, 2023 |  |  | December 31, 2022 |
Current Assets |  | $ | 1,451,877 |  |  | $ | 1,543,151 |
Non-current Assets |  |  | 686,206 |  |  |  | 739,472 |
Current Liabilities |  |  | 2,286,058 |  |  |  | 2,663,051 |
Non-current Liabilities |  |  | 347,193 |  |  |  | 103,447 |
Stockholders’ Equity |  |  | (495,168 | ) |  |  | (483,874 | )
Statement of operation
|  | Year Ended December 31, |
|  | 2023 |  |  | 2022 |
Net sales |  | $ | 734 |  |  | $ | 30,162 |
Gross profit |  |  | 289 |  |  |  | 8,239 |
Net loss |  |  | (1,194,797 | ) |  |  | (1,274,539 | )
Share of losses from investments accounted for using the equity method |  |  | (221,888 | ) |  |  | - |
(b) | Rgene Corporation (the “Rgene”)
Both Rgene and the Company are under common control by Dr. Tsung-Shann Jiang, the CEO and chairman of the BioLite Inc. Since Dr. Tsung-Shann Jiang is able to exercise significant influence, but not control, over the Rgene, the Company determined to use the equity method to accounts for its equity investment as prescribed in ASC 323, Investments—Equity Method and Joint Ventures (“ASC 323”). Equity method adjustments include the Company’s proportionate share of investee’s income or loss and other adjustments required by the equity method. As of December 31, 2023 and 2022, the Company owns 26.65% and 26.65% common stock shares of Rgene, respectively. Summarized financial information for the Company’s equity method investee, Rgene, is as follows: Balance Sheets
|  | December 31, 2023 |  |  | December 31, 2022 |
Current Assets |  | $ | 50,538 |  |  | $ | 68,302 |
Non-current Assets |  |  | 250,716 |  |  |  | 303,893 |
Current Liabilities |  |  | 2,591,960 |  |  |  | 2,478,868 |
Non-current Liabilities |  |  | 811 |  |  |  | 2,441 |
Shareholders’ Deficit |  |  | (2,291,517 | ) |  |  | (2,481,309 | )
Statement of operations
|  | Year Ended December 31, |
|  | 2023 |  |  | 2022 |
Net sales |  | $ | - |  |  | $ | - |
Gross Profit |  |  | - |  |  |  | - |
Net loss |  |  | (291,522 | ) |  |  | (1,550,123 | )
Share of loss from investments accounted for using the equity method |  |  | - |  |  |  | - |
(4) | Disposition of long-term investment
During the years ended December 31, 2023 and 2022, there is no disposition of long-term investment.
| (5) | Loss on investment in equity securities
The components of loss on investment in equity securities for each period were as follows:
|  | Year Ended December 31, |
|  | 2023 |  |  | 2022 |
Share of equity method investee losses |  | $ | (221,888 | ) |  | $ | - |

X
- Definition The entire disclosure for investment. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/320/tableOfContent Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Topic 321 -Publisher FASB -URI https://asc.fasb.org/321/tableOfContent Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Topic 325 -Publisher FASB -URI https://asc.fasb.org/325/tableOfContent + Details
Name: | us-gaap_InvestmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_LongTermInvestmentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration